Production (Stage)
Bicycle Therapeutics plc
BCYC
$8.05
-$0.05-0.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.98M | 3.71M | 2.68M | 9.36M | 19.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.98M | 3.71M | 2.68M | 9.36M | 19.53M |
| Cost of Revenue | 57.27M | -60.82M | 45.65M | 38.30M | 32.95M |
| Gross Profit | -47.29M | 68.24M | -42.97M | -28.94M | -13.42M |
| SG&A Expenses | 22.91M | 15.30M | 20.87M | 17.71M | 18.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.18M | 71.37M | 66.52M | 56.01M | 51.25M |
| Operating Income | -70.20M | -67.66M | -63.85M | -46.65M | -31.72M |
| Income Before Tax | -61.84M | -52.94M | -54.25M | -39.70M | -26.91M |
| Income Tax Expenses | -1.09M | -1.08M | -3.45M | 115.00K | -350.00K |
| Earnings from Continuing Operations | -60.75M | -51.85M | -50.80M | -39.81M | -26.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.75M | -51.85M | -50.80M | -39.81M | -26.56M |
| EBIT | -70.20M | -67.66M | -63.85M | -46.65M | -31.72M |
| EBITDA | -68.57M | -65.96M | -61.67M | -45.01M | -30.06M |
| EPS Basic | -0.88 | -0.75 | -0.74 | -0.77 | -0.62 |
| Normalized Basic EPS | -0.56 | -0.52 | -0.48 | -0.48 | -0.40 |
| EPS Diluted | -0.88 | -0.75 | -0.74 | -0.77 | -0.62 |
| Normalized Diluted EPS | -0.56 | -0.52 | -0.48 | -0.48 | -0.40 |
| Average Basic Shares Outstanding | 69.20M | 69.05M | 68.99M | 51.99M | 42.56M |
| Average Diluted Shares Outstanding | 69.20M | 69.05M | 68.99M | 51.99M | 42.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |